Short-acting Insulin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Published: January 17, 2022 |

Mordor Intelligence Pvt Ltd | 143 Pages | Delivery time: 2-3 business days

Price

Description
Table of Contents

Add to Compare

The short-acting insulin market (henceforth referred to as the market studied) was valued at USD 8.85 billion in 2020, and it is expected to reach a value of USD 9.39 billion by 2026, registering a CAGR of 1.15% during the period 2021-2026 (henceforth referred to as the forecast period).

The COVID-19 outbreak has exerted a tremendous strain on the healthcare framework in some countries. Moreover, people with chronic conditions are more at risk if contracted by COVID-19. For example, diabetic patients' lives are at high risk compared to normal people. Therefore, the usage of short-acting insulins increased in 2021 due to COVID-19.

Currently, there are five main types of insulins (regular insulin, NPH, short-acting analogs, basal analogs, and pre-mixed insulin) being sold globally. Generally, insulin analogs are priced much higher than regular insulin or NPH, as they are bioengineered with altered amino-acid sequences to provide the desired chemical properties. In recent days, usage of short-acting analogs has been increasing due to the increasing Type 1 diabetes population.

Key Market Trends

Increase in Type 1 Diabetes Population

Diabetes is a chronic, life-threatening disease with no known cure. It has emerged as a global epidemic and affected millions, worldwide. Moreover, Type 1 diabetes is caused due to an immune system malfunction. Hence, Type 1 diabetes can be characterized as insulin-requiring.

Currently, China has the highest number of diabetes patients in the world. However, the prevalence of diabetes in China has increased substantially over the past decade. In 2020, China had about 126.80 million diabetic patients, and this number is expected to reach 138.42 million by the end of 2026. China's urbanization and rising living standards, leading to reduced physical activity and unhealthy diets, are the major factors behind the soaring prevalence of diabetes. In 2020, Type 1 diabetes patients accounted for 9.8% of the total diabetes population in China.

The country is witnessing a significant increase in the number of generic drug manufacturers. Furthermore, leading global players in the market studied are facing strong competition from regional players.

The United States Held the Highest Market Share in 2020

In 2020, the United States accounted for a majority of the revenue share (about 96%) in the market, mainly due to the increasing diabetic population in the country. According to a recent survey, about 9.4% of the total US population is diabetic, and about 1.75 million Americans are diagnosed with diabetes every year.

The United States accounts for the highest sales of Humalog across the world, with over 56% of the market share in 2020. As a result, most diabetes drug manufacturing companies consider the country a critical market for improving overall global sales. In the United States, Humalog is available in different varieties under names, like Humalog Mix 75/25, Humalog U-100, Humalog U-200, and Humalog Mix 50/50, for the treatment of diabetes.

Competitive Landscape

The short-acting insulin market is mainly consolidated, with leading companies, like Sanofi, Novo Nordisk, and Eli Lilly, having a strong market presence. Each of these companies has established its brands in the market. However, due to intense competition in the local markets, these manufacturers have to put a lot of effort into penetrating these markets.

Hence, they employ powerful competitive strategies to improve their foothold in the market. Additionally, the high profitability of the market provides an incentive for several generic insulins (biosimilars) manufacturers and major companies trying to introduce innovative products.

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support

Product Code: 71982

1 INTRODUCTION

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET INSIGHTS

4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Industry Attractiveness - Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Drug (Value and Volume, 2016-2026)
- 5.1.1 Short-acting Insulins
  - 5.1.1.1 Apidra (Glulisine)
  - 5.1.1.2 Novolog/Novorapid
  - 5.1.1.3 Humalog (Lispro)
  - 5.1.1.4 Novolin (Actrapid)
  - 5.1.1.5 Insuman
  - 5.1.1.6 Humulin
  - 5.1.1.7 FIASP
  - 5.1.1.8 Admelog
5.2 By Geography
- 5.2.1 North America
  - 5.2.1.1 United States (Value and Volume, 2016-2026)
  - 5.2.1.1.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.1.2 Canada (Value and Volume, 2016-2026)
  - 5.2.1.2.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.1.3 Rest of North America (Value and Volume, 2016-2026)
  - 5.2.1.3.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
- 5.2.2 Europe
  - 5.2.2.1 United Kingdom (Value and Volume, 2016-2026)
  - 5.2.2.1.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.2.2 Germany (Value and Volume, 2016-2026)
  - 5.2.2.2.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.2.3 France (Value and Volume, 2016-2026)
  - 5.2.2.3.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.2.4 Italy (Value and Volume, 2016-2026)
  - 5.2.2.4.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.2.5 Spain (Value and Volume, 2016-2026)
  - 5.2.2.5.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.2.6 Russia (Value and Volume, 2016-2026)
  - 5.2.2.6.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.2.7 Rest of Europe (Value and Volume, 2016-2026)
  - 5.2.2.7.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
- 5.2.3 Latin America
  - 5.2.3.1 Mexico (Value and Volume, 2016-2026)
  - 5.2.3.1.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.3.2 Brazil (Value and Volume, 2016-2026)
  - 5.2.3.2.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.3.3 Rest of Latin America (Value and Volume, 2016-2026)
  - 5.2.3.3.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
- 5.2.4 Asia-Pacific
  - 5.2.4.1 Japan (Value and Volume, 2016-2026)
  - 5.2.4.1.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.4.2 South Korea (Value and Volume, 2016-2026)
  - 5.2.4.2.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.4.3 China (Value and Volume, 2016-2026)
  - 5.2.4.3.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.4.4 India (Value and Volume, 2016-2026)
  - 5.2.4.4.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.4.5 Australia (Value and Volume, 2016-2026)
  - 5.2.4.5.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.4.6 Vietnam (Value and Volume, 2016-2026)
  - 5.2.4.6.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.4.7 Malaysia (Value and Volume, 2016-2026)
  - 5.2.4.7.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.4.8 Indonesia (Value and Volume, 2016-2026)
  - 5.2.4.8.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.4.9 The Philippines (Value and Volume, 2016-2026)
  - 5.2.4.9.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.4.10 Thailand (Value and Volume, 2016-2026)
  - 5.2.4.10.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2016-2026)
  - 5.2.4.11.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
- 5.2.5 Middle-East and Africa
  - 5.2.5.1 Saudi Arabia (Value and Volume, 2016-2026)
  - 5.2.5.1.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.5.2 Iran (Value and Volume, 2016-2026)
  - 5.2.5.2.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.5.3 Egypt (Value and Volume, 2016-2026)
  - 5.2.5.3.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.5.4 Oman (Value and Volume, 2016-2026)
  - 5.2.5.4.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.5.5 South Africa (Value and Volume, 2016-2026)
  - 5.2.5.5.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)
  - 5.2.5.6 Rest of Middle-East and Africa (Value and Volume, 2016-2026)
  - 5.2.5.6.1 Short-acting Insulins (Apidra, Novolog, Humalog, Novolin, Insuman, Humulin, FIASP, Admelog)

6 MARKET INDICATORS

6.1 Type-1 Diabetes Population (2016-2026)
6.2 Type-2 Diabetes Population (2016-2026)

7 COMPETITIVE LANDSCAPE

7.1 Company Profiles
- 7.1.1 Novo Nordisk AS
- 7.1.2 Sanofi Aventis
- 7.1.3 Eli Lilly
7.2 Company Share Analysis
- 7.2.1 Novo Nordisk AS
- 7.2.2 Sanofi Aventis
- 7.2.3 Eli Lilly
- 7.2.4 Other Companies